Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
daGOAT Model-guided Prevention of Severe Acute GvHD
NCT07588945Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07588945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588945.